Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

开始日期2025-07-01

申办/合作机构

Wake Forest School of Medicine

NCT06693726

/ Not yet recruiting临床4期IIT

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

开始日期2025-04-01

申办/合作机构

University of Iowa

NCT06615102

/ Not yet recruiting临床3期IIT

A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

开始日期2025-01-01

申办/合作机构

Westfälische Wilhelms-Universität Münster

[+1]

100 项与血管紧张素II 相关的临床结果

登录后查看更多信息

100 项与血管紧张素II 相关的转化医学

登录后查看更多信息

100 项与血管紧张素II 相关的专利（医药）

登录后查看更多信息

12,771

项与血管紧张素II 相关的文献（医药）

2025-04-01·HYPERTENSION

Central Interaction of 2-Methoxyestradiol and Lipoxygenase in AngII-Hypertension

Article

作者: Dutta, Shubha R. ; Singh, Purnima ; Shin, Ji Soo ; Song, Chi Young ; Malik, Kafait U.

BACKGROUND::

Our previous findings that arachidonic acid-12/15-lipoxygenase (LOX)-generated metabolite 12(S)-HETE contributes to angiotensin II (AngII)-induced hypertension and 17β-estradiol protects from AngII-induced hypertension via its cytochrome P450 (CYP)1B1-generated metabolite 2-methoxyestradiol in the paraventricular nucleus (PVN) in female mice led us to test the hypothesis that 2-methoxyestradiol acts by inhibiting the LOX/12(S)-HETE in the PVN.

METHODS::

AngII was infused subcutaneously by osmotic pumps for 2 weeks in wild-type, LOX-knockout (LOXKO), and CYP1B1KO female mice. The blood pressure was measured by tail-cuff/radiotelemetry. Adenovirus (Ad)-GFP (green fluorescence protein)-LOX-short hairpin RNA, Ad-GFP-LOX-DNA, 12(S)-HETE, and 2-methoxyestradiol were injected selectively in PVN or intracerebroventricularly. Histological, immunohistochemical, and biochemical techniques were used to determine pathophysiological changes caused by various interventions.

RESULTS::

AngII-induced hypertension that was exaggerated in CYP1B1KO compared with wild-type mice was minimized by PVN-LOX knockdown with Ad-LOX-short hairpin RNA and restored by PVN-LOX reconstitution with Ad-LOX-DNA in intact-LOXKO mice and exacerbated in ovariectomized-LOXKO mice. Furthermore, intracerebroventricular-12(S)-HETE restored AngII-induced increases in blood pressure, autonomic impairment, neuroinflammation, and renal pathogenesis in intact-LOXKO mice, which were exacerbated in ovariectomized-LOXKO mice. Intracerebroventricular-2-methoxyestradiol that reduced the LOX expression and 12(S)-HETE content in PVN minimized AngII effects mentioned above in ovariectomized-LOXKO mice transduced with intracerebroventricular-Ad-LOX-DNA.

CONCLUSIONS::

These data suggest that 2-methoxyestradiol protects against AngII-induced hypertension and associated pathogenesis, most likely by inhibiting LOX/12(S)-HETE actions in the PVN of female mice. Therefore, the selective LOX inhibitors or 12(S)-HETE receptor antagonists could be useful in treating hypertension and its pathogenesis in postmenopausal, hypoestrogenic women or females with ovarian failure.

2025-04-01·HYPERTENSION

Role of Ciliary Neurotrophic Factor in Angiotensin II-Induced Hypertension

Article

作者: Kantauskaite, Marta ; Arifaj, Denada ; Rio, Marc ; Quack, Ivo ; Meuth, Sven G. ; Meister, Jaroslawna ; Alesutan, Ioana ; Argov, Doron ; Potthoff, Sebastian A. ; Rump, Lars C. ; Mori, Yuri ; Stegbauer, Johannes ; Amin, Ehsan ; Park, Joon-Keun ; Voelkl, Jakob ; Linker, Ralf A. ; Loirand, Gervaise ; Yang, Guang

BACKGROUND::

Ciliary neurotrophic factor (CNTF), mainly known for its neuroprotective properties, belongs to the IL-6 (interleukin-6) cytokine family. In contrast to IL-6, the effects of CNTF on the vasculature have not been explored. Here, we examined the role of CNTF in AngII (angiotensin II)-induced hypertension.

METHODS::

Hypertension was chronically induced with AngII (1000 ng/kg per minute, osmotic mini-pumps, 14 days) in CNTF-knockout and wild-type mice (with or without nephrectomy and 1% NaCl drinking water). Blood pressure was measured by tail-cuff and radiotelemetry. Effects of CNTF on vascular function and the JAK2/STAT3 pathway were measured in vivo, in the isolated perfused kidney, and in mouse and human vascular smooth muscle cells.

RESULTS::

At baseline, systolic blood pressure was similar between both groups. During AngII infusion, blood pressure increase was significantly attenuated and hypertensive heart and kidney damage was significantly attenuated in CNTF-knockout compared with wild-type mice. Accordingly, renal pressor response to AngII but not KCl or phenylephrine was significantly decreased in CNTF-knockout compared with wild-type mice. Acute CNTF (5 µmol/L) administration nearly restored the AngII-dependent renal pressor response. Chronic CNTF treatment in CNTF-knockout mice increased blood pressure response to AngII to levels observed in wild-type mice. CNTF augments AngII-induced activation of the JAK2/STAT3 pathway in vitro in vascular smooth muscle cells. The significance of this interaction was shown, as the increase in renal pressor response by CNTF was abolished by JAK2/STAT3 inhibitors.

CONCLUSIONS::

Our results demonstrate a major impact of CNTF on blood pressure regulation by modulating AngII-induced pressor response via a JAK2/STAT3-dependent mechanism and indicate that CNTF is an important regulatory cytokine in hypertension.

2025-04-01·Biochemical genetics

miR-29b-3p Affects the Hypertrophy of Ligamentum Flavum in Lumbar Spinal Stenosis and its Mechanism

Article

作者: Jiang, Zehua ; Hu, Wei ; Zhang, Hongjie ; Zhu, Rusen ; Hu, Jiashao ; Hong, Zhixiong

To explore the effect of miR-29b-3p on fibrosis and hypertrophy of ligamentum flavum (LF) in lumbar spinal stenosis (LSS) and its underlying mechanism. Patients with LSS and lumbar disc herniation (LDH) (control) undergoing posterior lumbar laminectomy were included in this study. Human LF samples were obtained for LF cell isolation, RNA, and protein extraction. Histomorphological analysis of LF was performed using hematoxylin-eosin (HE) staining. After isolation, culture, and transfection of primary LF cells, different transfection groups were constructed: NC-mimic, miR-29b-3p-mimic, NC-inhibitor, and miR-29b-3p-inhibitor. Quantitative real time polymerase chain reaction (qRT-PCR) was performed to detect the expression of miR-29b-3p in LF and LF cells. Western blot analysis detected the protein expressions of P16 and CyclinD1. ELISA detected the protein expressions of TGF-β1, Smad2, Smad3, TLR4, Type I collagen, and Type III collagen. Finally, LF cell viability was detected using the Cell Counting Kit-8 (CCK8) assay. The thickness of LF was significantly thicker in the LSS group compared to the LDH group (p < 0.05), accompanied by a higher calcification degree, more fibroblasts, and a larger area of collagen fiber proliferation. miR-29b-3p expression was significantly lower in LSS-derived LF tissues and cells than in LDH-derived tissues and cells (both p < 0.05). Compared to the NC-mimic group, the miR-29b-3p-mimic group exhibited significantly higher miR-29b-3p expression, decreased protein expressions of Type I collagen, Type III collagen, TGF-β1, Smad2, Smad3, TLR4, P16, and CyclinD1, and inhibited LF cell proliferation (all p < 0.05). As expected, the miR-29b-3p-inhibitor group displayed contrasting expression patterns (all p < 0.05). Compared to the phosphate buffer saline (PBS) group, the Trimethylamine-N-Oxide (TMAO) group showed significantly increased expressions of TGF-β1, Smad2, Smad3, TLR4, Type I collagen, Type III collagen, P16, and CyclinD1, as well as enhanced LF cell proliferation (all p < 0.05). However, there was no significant difference between the TMAO group and the Ang II group (all p > 0.05). Upregulation of miR-29b-3p expression may play a role in improving LF fibrosis and hypertrophy in LSS by inhibiting P16 expression and suppressing the activation of the TGF-β/Smad signaling pathway. This finding offers new insights into future gene modification therapy for this patient population.

项与血管紧张素II 相关的新闻（医药）

2025-02-16

·信狐药迅

恒瑞JAK1抑制剂艾玛昔替尼软膏申报上市提交上市申请|新受理（2.10-2.16）

本周药品注册受理数据，分门别类呈现，一目了然。(2.10-2.16）新药上市申请药品名称企业注册分类受理号艾玛昔替尼软膏江苏恒瑞医药股份有限公司1CXHS2500018枸地氯雷他定口服液合肥恩瑞特药业有限公司2.2;2.4CXHS2500017 新药临床申请药品名称企业注册分类受理号HEC-007注射液广东东阳光药业股份有限公司1CXHL2500199HEC-007注射液东莞市东阳光生物药研发有限公司1CXHL2500198HEC-007注射液东莞市东阳光生物药研发有限公司1CXHL2500197SAL0140片深圳信立泰药业股份有限公司1CXHL2500196SAL0140片深圳信立泰药业股份有限公司1CXHL2500195AHB-137注射液杭州浩博医药有限公司1CXHL2500193MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500191MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500190MT-1207缓释片原研药港生命科学(辽宁)集团有限公司1CXHL2500189注射用RS202227山东泰合医药科技有限公司2.2CXHL2500194BTS0327江苏诺和必拓新药研发有限公司2.2CXHL2500192PA9060乳膏安徽劳斯多斯医药科技有限公司2.2;2.4CXHL2500188PA9060乳膏安徽劳斯多斯医药科技有限公司2.2;2.4CXHL2500186普卢格列汀二甲双胍缓释片(Ⅱ)石药集团欧意药业有限公司2.3CXHL2500187普卢格列汀二甲双胍缓释片(Ⅰ)石药集团欧意药业有限公司2.3CXHL2500185DYTH201片山西德元堂药业有限公司2.3CXHL2500184DYTH201片山西德元堂药业有限公司2.3CXHL2500183重组人乳头瘤病毒九价疫苗(汉逊酵母)(BFA58佐剂)江苏瑞科生物技术股份有限公司1.3CXSL2500139注射用MK-3120默沙东研发(中国)有限公司1CXSL2500148人脐带间充质干细胞注射液武汉汉密顿生物科技股份有限公司1CXSL2500147人脐带间充质干细胞注射液武汉汉密顿生物科技股份有限公司1CXSL2500146注射用AS1501深圳市中科艾深医药有限公司1CXSL2500145注射用BAT7111百奥泰生物制药股份有限公司1CXSL2500140注射用BL-B01D1成都百利多特生物药业有限责任公司1CXSL2500144注射用ESG406上海诗健生物科技有限公司1CXSL2500143注射用XTL6001上海西泰利生物医药科技有限公司1CXSL2500142IAH0968盛禾(中国)生物制药有限公司1CXSL2500141TQB2210注射液正大天晴药业集团南京顺欣制药有限公司1CXSL2500136GZR102甘李药业山东有限公司1CXSL2500134CM326注射液上海津曼特生物科技有限公司1CXSL2500133CM326注射液上海津曼特生物科技有限公司1CXSL2500132自体淋巴细胞注射液康爱瑞浩生物医药(浙江)股份有限公司1CXSL2500131注射用卡瑞利珠单抗苏州盛迪亚生物医药有限公司2.2CXSL2500135 仿制药申请药品名称企业注册分类受理号酒石酸美托洛尔注射液白云山东泰商丘药业有限公司3CYHS2500749琥珀酸曲格列汀片南京万融健诚医药科技有限公司3CYHS2500748琥珀酸曲格列汀片南京万融健诚医药科技有限公司3CYHS2500747盐酸曲唑酮片江苏万高药业股份有限公司3CYHS2500738盐酸曲唑酮片江苏万高药业股份有限公司3CYHS2500737盐酸半胱氨酸注射液北京柏雅联合药物研究所有限公司3CYHS2500743复方聚乙二醇电解质散(儿童型)山东益康药业股份有限公司3CYHS2500725注射用硫酸多黏菌素B江苏迪赛诺制药有限公司3CYHS2500724复方聚乙二醇(3350)电解质口服溶液广州一品红制药有限公司3CYHS2500723注射用硫酸多黏菌素B广东金城金素制药有限公司3CYHS2500722硝酸甘油注射液广州合和医药有限公司3CYHS2500719硝酸甘油注射液广州合和医药有限公司3CYHS2500718比拉斯汀口腔崩解片珠海市汇通达医药有限公司3CYHS2500717联苯苄唑溶液安徽四环科宝制药有限公司3CYHS2500716注射用乳糖酸红霉素海韬新药研发(江苏)有限公司3CYHS2500734琥珀酸亚铁片江西泰吉立生物医药科技有限公司3CYHS2500733盐酸多巴胺注射液成都恒瑞制药有限公司3CYHS2500732盐酸多巴胺注射液成都恒瑞制药有限公司3CYHS2500731二羟丙茶碱注射液成都华宇制药有限公司3CYHS2500730盐酸奥普力农注射液山东健滨医药科技有限公司3CYHS2500729复合磷酸氢钾注射液成都诺和晟鸿生物制药有限公司3CYHS2500728二硫化硒洗剂杭州和泽坤元药业有限公司3CYHS2500720硝酸甘油注射液江西人可医药科技有限公司3CYHS2500714硝酸甘油注射液江西人可医药科技有限公司3CYHS2500713氨磺必利口服溶液南京恒道医药科技股份有限公司3CYHS2500712艾曲泊帕乙醇胺干混悬剂郑州泰丰制药有限公司3CYHS2500700硫酸特布他林口服溶液山东致泰医药技术有限公司3CYHS2500699盐酸布比卡因注射液济南东方开元医药新技术有限公司3CYHS2500708奥硝唑注射液四环医药(郑州)有限公司3CYHS2500706奥硝唑注射液四环医药(郑州)有限公司3CYHS2500705布美他尼注射液江西人可医药科技有限公司3CYHS2500702布美他尼注射液江西人可医药科技有限公司3CYHS2500701盐酸甲氧氯普胺注射液江西人可医药科技有限公司3CYHS2500693注射用盐酸罗沙替丁醋酸酯湖北潜龙药业有限公司3CYHS2500692双嘧达莫片四川天杏汇医药科技有限公司3CYHS2500691氧(气态)大荔县振远工业气体分装有限公司4CYHS2500750枸橼酸西地那非口腔崩解片河南君善生物技术有限公司4CYHS2500746双氯芬酸钠缓释片珠海润都制药股份有限公司4CYHS2500745双氯芬酸钠缓释片珠海润都制药股份有限公司4CYHS2500744赛洛多辛胶囊江苏联环药业股份有限公司4CYHS2500739奥卡西平片浙江恒研医药科技有限公司4CYHS2500741奥卡西平片浙江恒研医药科技有限公司4CYHS2500740甲磺酸沙非胺片常州四药制药有限公司4CYHS2500736甲磺酸沙非胺片常州四药制药有限公司4CYHS2500735甲磺酸仑伐替尼胶囊山东鲁抗医药股份有限公司4CYHS2500742精氨酸布洛芬颗粒湖北亨迪药业股份有限公司4CYHS2500727精氨酸布洛芬颗粒湖北亨迪药业股份有限公司4CYHS2500726盐酸氮斯汀滴眼液武汉五景药业有限公司4CYHS2500721达格列净二甲双胍缓释片(I)江苏安必生制药有限公司4CYHS2500703夫西地酸乳膏杭州朱养心药业有限公司4CYHS2500711莫匹罗星软膏国药控股鑫烨(湖北)医药有限公司4CYHS2500704左氧氟沙星滴眼液安徽康融药业有限公司4CYHS2500715玻璃酸钠滴眼液江苏万高药业股份有限公司4CYHS2500710玻璃酸钠滴眼液江苏万高药业股份有限公司4CYHS2500709左西孟旦注射液仁合益康汇泽药业河北有限公司4CYHS2500707盐酸艾司洛尔注射液广东南国药业有限公司4CYHS2500698枸橼酸莫沙必利片福建省宝诺医药研发有限公司4CYHS2500695美阿沙坦钾片珠海润都制药股份有限公司4CYHS2500694利格列汀片江苏康缘药业股份有限公司4CYHS2500690布瑞哌唑片重庆圣华曦药业股份有限公司4CYHS2500689布瑞哌唑片重庆圣华曦药业股份有限公司4CYHS2500688头孢托仑匹酯颗粒苏州盛达药业有限公司4CYHS2500697头孢托仑匹酯颗粒苏州盛达药业有限公司4CYHS2500696左卡尼汀注射液广州泽盛药业科技有限公司4CYHS2500687左卡尼汀注射液广州泽盛药业科技有限公司4CYHS2500686乌司奴单抗注射液(静脉输注)杭州中美华东制药有限公司3.3CXSS2500028米诺地尔泡沫剂(男用)山东京卫制药有限公司3CYHL2500041托吡司特片长春海悦药业股份有限公司3CYHL2500040托吡司特片长春海悦药业股份有限公司3CYHL2500039铜[64Cu]氧奥曲肽注射液江苏华益科技有限公司3CYHL2500038乙酰唑胺缓释胶囊海南灵康制药有限公司3CYHL2500037血管紧张素Ⅱ注射液宜昌人福药业有限责任公司3CYHL2500036琥珀酰明胶注射液内蒙古白医制药股份有限公司4CYHL2500035司美格鲁肽注射液太极集团重庆涪陵制药厂有限公司3.3CXSL2500138司美格鲁肽注射液太极集团重庆涪陵制药厂有限公司3.3CXSL2500137 进口申请药品名称企业注册分类受理号布地奈德吸入气雾剂INTECH BIOPHARM LTD5.1JXHS2500023美泊利珠单抗注射液GlaxoSmithKline Trading Services Limited2.2JXSS2500006美泊利珠单抗注射液GlaxoSmithKline Trading Services Limited2.2JXSS2500005西妥昔单抗注射液Merck Europe B.V.3.1JXSS2500012司美格鲁肽注射液Novo Nordisk A/S3.1JXSS2500011司美格鲁肽注射液Novo Nordisk A/S3.1JXSS2500010司美格鲁肽注射液Novo Nordisk A/S3.1JXSS2500009司美格鲁肽注射液Novo Nordisk A/S3.1JXSS2500008司美格鲁肽注射液Novo Nordisk A/S3.1JXSS2500007注射用A型肉毒毒素Ipsen Pharma3.1JXSS2500004LOU064片Novartis Pharma AG1JXHL2500026LOU064片Novartis Pharma AG1JXHL2500025LOU064片Novartis Pharma AG1JXHL2500024呼吸道合胞病毒疫苗Pfizer Inc.3.1JXSL2500026Nipocalimab注射液Janssen Research & Development, LLC1JXSL2500022Mosunetuzumab InjectionF. Hoffmann-La Roche Ltd.2.1JXSL2500024Mosunetuzumab InjectionF. Hoffmann-La Roche Ltd.2.1JXSL2500023艾加莫德α注射液argenx BV2.2JXSL2500025 中药相关申请药品名称企业注册分类受理号真武颗粒康普药业股份有限公司3.1CXZS2500007芍药甘草颗粒湖北济安堂药业股份有限公司3.1CXZS2500006当归六黄颗粒山东宏济堂制药集团股份有限公司3.1CXZS2500005双黄连口服液云南楚雄天利药业有限公司4CYZS2500002穿虎祛痛颗粒鲁南厚普制药有限公司1.1CXZL2500009复方芎蕲软胶囊四川省中医药科学院(四川省中药研究所)1.1CXZL2500008 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗申请上市

2024-12-27

·兰卫医学

【兰卫科普】高血压三项应用解析

兰卫科普 ——高血压三项应用解析一高血压三项应用解析高血压是指以体循环动脉血压（收缩压或舒张压）增高为主要特征（收缩压≥140毫米汞柱，舒张压≥90毫米汞柱），可伴有心、脑、肾等器官的功能或器质性损害的临床综合征。高血压是现代社会最常见的慢性病，也是心脑血管疾病最主要的危险因素，其发生发展与遗传、环境、生活方式等多种因素有关。在高血压的诊断和治疗过程中，肾素、醛固酮、血管紧张素三项指标具有重要临床意义。本文将详细阐述这三项指标在临床上的应用。肾素、醛固酮、血管紧张素是人体内调节血压的重要激素。肾素是肾小球旁器、球旁细胞释放的一种蛋白水解酶[1],主要由肾脏分泌，作用于血管紧张素原，生成血管紧张素I。血管紧张素I在血管紧张素转换酶的作用下，转化为血管紧张素II。血管紧张素II可以发挥内分泌、旁分泌和胞分泌的作用[2]。血管紧张素II具有强烈的收缩血管作用，同时促进肾上腺皮质分泌醛固酮。血管紧张素II是肾素-血管紧张素-醛固酮系统调节血压的一个直接作用物质。同时，血管紧张素II也能够作为促生长因子直接促进血管内皮细胞的增生[3]。醛固酮是由肾上腺皮质球状带细胞合成和分泌的一种盐皮质激素，主要作用于肾脏远曲小管和肾皮质集合管，增加对钠离子的重吸收和促进钾离子的排泄，也作用于髓质集合管，促进氢离子的排泄，酸化尿液[4]。发病率高致残率高致死率高知晓率低治疗率低控制率低我国现有高血压患者2.45亿，而知晓率仅51.6%，治疗率仅45.8%，控制率仅16.8%（中国高血压防治指南2018）。与美国相比，知晓率、治疗率、控制率分别达到82.7%、75.6%、51.8%。[5] 二临床应用原发性高血压：病因不明，绝大多数需要长期、甚至终生坚持治疗。继发性高血压：身体的一些器官或系统病变所导致的临床表现，病因相对明确，对症、对因治疗可以治愈或缓解。文献报道新疆地区继发性高血压发病率在高血压中的占比1999年为9.6%、2005年为14.76%、2008年为39.30%、2014年超过40%，呈现逐年的上升的趋势[6]，这种趋势在其它相关文献中也得到了佐证，如研究者莫剑梅等分析发现继发性高血压发病率占比2011年为27%[7]，而到了2020年，王梦琳等报道继发性高血压占比为39.26%[8]，趋势明确，上升幅度呈现地域间的差异，这种现象需引起社会的关注。笔者通过查阅资料[9-10]，总结继发性高血压的常见成因，见图1。图1 继发性高血压常见病因二 01肾素临床应用（1）诊断高血压病因：肾素活性检测有助于鉴别原发性高血压和继发性高血压。原发性高血压患者肾素活性多正常或偏低，继发性高血压患者肾素活性多升高。（2）判断高血压严重程度：肾素活性与高血压严重程度呈正相关，肾素活性越高，血压越高，病情越严重。（3）指导降压治疗：肾素活性检测有助于选择合适的降压药物。对于肾素活性高者，选用ACEI（血管紧张素转换酶抑制剂）或ARB（血管紧张素受体拮抗剂）类降压药物效果较好。二 02醛固酮临床应用（1）诊断醛固酮增多症：醛固酮增多症是引起继发性高血压的常见病因，通过检测醛固酮/肾素比值（ARR）有助于诊断该病。（2）判断高血压病情：醛固酮水平与高血压病情呈正相关，醛固酮水平越高，病情越严重。（3）指导降压治疗：对于醛固酮增多症患者，选用醛固酮受体拮抗剂如螺内酯等药物，可降低血压，改善病情。二 03血管紧张素临床应用（1）诊断高血压病因：血管紧张素II水平有助于鉴别原发性高血压和继发性高血压。原发性高血压患者血管紧张素II水平多正常，继发性高血压患者血管紧张素II水平多升高。（2）判断高血压严重程度：血管紧张素II水平与高血压严重程度呈正相关，血管紧张素II水平越高，血压越高，病情越严重。（3）指导降压治疗：血管紧张素转换酶抑制剂（ACEI）和血管紧张素受体拮抗剂（ARB）类药物，通过抑制血管紧张素II的生成，降低血压，改善病情。三三项联合应用优势（1）提高诊断准确性：三项指标联合检测，有助于更全面地了解高血压患者的病情，提高诊断准确性。（2）优化治疗方案：根据三项指标检测结果，制定个体化的治疗方案，提高治疗效果。（3）预防并发症：三项指标联合检测，有助于发现潜在的危险因素，及时干预，预防并发症。四临床应用注意事项（1）标本采集：采集血液标本时，应避免压迫血管，确保样本质量。（2）检测方法：选择可靠的检测方法，确保检测结果的准确性。（3）结果解读：结合患者的病史、临床表现和其他检查结果，综合分析三项指标，避免误诊。（4）治疗监测：在治疗过程中，定期检测三项指标，评估治疗效果，调整治疗方案。结语总之，高血压三项指标在临床上的应用具有重要意义，有助于诊断高血压病因、判断病情严重程度和指导降压治疗。合理运用这三项指标，可以提高高血压的诊疗水平，降低患者的并发症风险，改善预后。参考文献： [1] Measurement of plasma renin:a critical review of methodology. JRAAS，2010;11(2):89-90. [2] 杨钢主编.内分泌生理与病理生理学.天津科学技术出版社，2000年5月第二版。 [3] M Miyawaki,T Okutani, R Higuchi,N Yoshikawa Plasma angiotensin II concentrations in the early neonatal period.Arch Dis Child Fetal Neonatal Ed2006;91:F359-F362. [4] 杨钢主编.内分泌生理与病理生理学.天津科学技术出版社，2000年5月第二版。 [5] 《中国心血管健康与疾病报告2019》、《中国高血压防治指南2019》。 [6] 李南方，常桂娟，王新玲，等.继发性高血压筛查平台的建设和成功诊断[J].中华医学会第十五次全国心血管病学大会,2013,46-50. [7] 莫剑梅，刘唐威，黄容杰，等.518例初诊高血压患者病因分析[J].心血管系统疾病，2012，10.16121/j.cnki.cn 45-1347/r.2012.02.035. [8]王梦琳，王浩，赵海鹰等.高血压专科3706例住院继发性高血压患者病因构成分析[J].中华高血压杂志，2020，28（02）：155-162. [9]潘晓明，乔森，尹大维，等.探讨高血压的病因、临床治疗方案及效果[J].智慧健康，2022，6（25）：55-57. [10]张宁.高血压的病因及临床治疗[J].中国社区医师，2017，33（02）：36-37. 本文由南京子公司张翠提供指导老师詹喜焱、熊进校正陈子祥

临床结果

2024-12-17

·GlobeNewswire-Health Care

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US). Innoviva Specialty Therapeutics is a US-based biopharmaceutical company with an established hospital sales force and a core competence in commercializing anti-infective medicines. David Veitch, Chief Executive Officer of Basilea, stated: “We are very pleased with our collaboration with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US. The company is a highly committed, focused and capable partner that shares our vision and ambitions for Zevtera in the US. They also have recent experience of launching a hospital antibiotic in the US. We are looking forward to working with Innoviva Specialty Therapeutics towards a successful launch and bringing Zevtera to patients in need in the US.” “With this agreement, Zevtera will become an important asset in our company’s portfolio, allowing us to advance our strategy of providing differentiated therapies in infectious disease and critical care,” said Pavel Raifeld, Chief Executive Officer, Innoviva, Inc. “There is a significant medical need for treatments targeting complicated Staphylococcus aureus infections, particularly Staphylococcus aureus bacteremia. We are therefore excited to bring this important new medicine to patients who are suffering from these severe infections.” Under the terms of the agreement, Basilea will receive a USD 4 million upfront payment and tiered royalties on net sales in the high-teens to mid-twenties percentage range. Basilea will be eligible to receive sales milestones of up to USD 223 million. In addition, Innoviva Specialty Therapeutics will purchase its demand of Zevtera drug product from Basilea. Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.1 In several countries in Europe and beyond, the brand is currently approved and marketed as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Basilea has entered into license and distribution agreements covering more than 80 countries. In the United States, Zevtera is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).2 Basilea’s ceftobiprole phase 3 program is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work. Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. References Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: December 15, 2024] Full US prescribing information: https://www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk The content above comes from the network. if any infringement, please contact us to modify.

引进/卖出上市批准

100 项与血管紧张素II 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	血管紧张素II	C01CX09	DB11842

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
分布性休克	欧盟	PAION AG	2019-08-23
分布性休克	冰岛	PAION AG	2019-08-23
分布性休克	列支敦士登	PAION AG	2019-08-23
分布性休克	挪威	PAION AG	2019-08-23
低血压	欧盟	PAION AG	2019-08-23
低血压	冰岛	PAION AG	2019-08-23
低血压	列支敦士登	PAION AG	2019-08-23
低血压	挪威	PAION AG	2019-08-23
脓毒性休克	欧盟	PAION AG	2019-08-23
脓毒性休克	冰岛	PAION AG	2019-08-23
脓毒性休克	列支敦士登	PAION AG	2019-08-23
脓毒性休克	挪威	PAION AG	2019-08-23
休克	美国	La Jolla Pharma LLC	2017-12-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝移植排斥反应	临床3期	美国	La Jolla Pharmaceutical Co.	2022-06-28
血管麻痹	临床3期	美国	La Jolla Pharmaceutical Co.	2022-06-28
脓毒症	临床3期	美国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	澳大利亚	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	比利时	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	加拿大	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	芬兰	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	法国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	德国	La Jolla Pharmaceutical Co.	2015-03-01
脓毒症	临床3期	新西兰	La Jolla Pharmaceutical Co.	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02338843 (ATHOS-3, Pubmed \| Crit Care)	临床3期	休克 baseline renin \| angiotensin-II \| renin/angiotensin-II ratio	-	Angiotensin-II	糧鹹簾簾膚憲遞夢鏇網(蓋壓構鑰艱繭鑰艱艱獵) = 遞鑰簾憲鏇齋夢餘廠蓋廠壓願鏇鹹艱鑰蓋餘鹽 (鹹醖襯簾餘積顧簾構膚, 0.35 ~ 2.83)	积极	2025-02-19
				Placebo	糧鹹簾簾膚憲遞夢鏇網(蓋壓構鑰艱繭鑰艱艱獵) = 願鬱簾簾夢積廠觸獵範廠壓願鏇鹹艱鑰蓋餘鹽 (鹹醖襯簾餘積顧簾構膚, -0.03 ~ 0.10) 更多
NCT04558359 (CTgov)	临床4期	急性肾损伤 \| 脓毒性休克	30	Standard of Care (Standard of Care Cohort)	構選積觸鏇憲選膚鑰顧(壓糧憲糧鹽壓襯遞顧顧) = 廠鹹網範鑰構積遞鬱鑰艱鹽衊構網齋醖壓積襯 (繭夢糧壓壓簾膚獵鏇壓, 繭窪簾鑰鏇構獵廠齋餘 ~ 構鏇齋鏇襯糧餘簾簾網) 更多	-	2024-09-04
				Angiotensin II (Angiotensin II Cohort)	構選積觸鏇憲選膚鑰顧(壓糧憲糧鹽壓襯遞顧顧) = 範窪衊顧廠鑰製醖鬱積艱鹽衊構網齋醖壓積襯 (繭夢糧壓壓簾膚獵鏇壓, 鏇膚衊糧鏇簾鏇蓋選壓 ~ 鹹築憲鹹願觸簾鏇鬱糧) 更多
ATS2024	N/A	成人呼吸窘迫综合征 \| 分布性休克	-	Angiotensin-II	鬱膚壓鏇觸簾夢衊構觸(選壓鑰鏇鹽獵鑰製廠範) = 淵鹹鏇顧顧膚顧鬱齋製膚蓋願遞鑰膚積蓋積遞 (範壓簾簾窪願衊願淵鹹, 160) 更多	-	2024-05-19
				Placebo	鬱膚壓鏇觸簾夢衊構觸(選壓鑰鏇鹽獵鑰製廠範) = 糧遞憲願壓繭蓋艱構製膚蓋願遞鑰膚積蓋積遞 (範壓簾簾窪願衊願淵鹹, 74) 更多
NCT01393782 (ATHOS, CTgov)	临床1期	脓毒性休克 \| 休克 \| 低血压	20	Angiotensin II (Angiotensin)	餘襯製醖製範廠醖遞衊(範襯構齋繭糧襯範鏇顧) = 顧夢鬱繭廠憲鬱遞餘製鹹襯簾鬱鏇積齋艱夢糧 (選廠艱襯襯鬱鹹製積鏇, 12.4) 更多	-	2024-04-12
				Angiotensin II (Control)	餘襯製醖製範廠醖遞衊(範襯構齋繭糧襯範鏇顧) = 襯顧範襯糧繭築齋艱齋鹹襯簾鬱鏇積齋艱夢糧 (選廠艱襯襯鬱鹹製積鏇, 29.3) 更多
ESC2024	N/A	休克	-	Angiotensin II	廠蓋積醖壓繭襯憲餘選(糧壓壓壓鑰網蓋顧鬱遞) = 醖選廠簾鑰鹽夢餘鹽糧鹽繭積艱願鬱簾壓鑰膚 (顧網衊廠窪鏇蓋膚膚遞, 41 ~ 56) 更多	-	2024-03-08
NCT02338843 (ATHOS-3, Pubmed \| Ann Intensive Care)	临床3期	急性呼吸窘迫综合征 \| 休克	81	Angiotensin-II	憲廠艱膚網選獵夢衊艱(顧醖遞壓衊膚簾憲蓋壓) = 鏇顧淵鬱鹽觸積膚範願鏇醖構衊廠範積夢廠簾 (糧遞鹽窪鹹顧顧糧鬱獵 ) 更多	积极	2023-12-16
				Placebo	憲廠艱膚網選獵夢衊艱(顧醖遞壓衊膚簾憲蓋壓) = 範顧廠襯憲製醖膚鹽製鏇醖構衊廠範積夢廠簾 (糧遞鹽窪鹹顧顧糧鬱獵 ) 更多
ATS2023	N/A	药物过量	-	Angiotensin II	鹹鏇築製積築願窪鬱齋(壓簾願獵艱餘網製鑰憲) = 製積範製選製鑰製衊鏇獵積膚選顧遞襯蓋艱鑰 (範膚齋醖範簾遞襯憲積 )	-	2023-05-21
NCT02338843 (ATHOS-3, Pubmed)	临床3期	休克	321	Angiotensin II	觸簾醖窪選糧齋鬱襯膚(積遞壓簾構遞淵鏇製願): HR = 0.509 (95% CI, 0.274 ~ 0.945), P-Value = 0.03 更多	-	2023-05-05
				Placebo
NCT04529005 (CTgov)	临床4期	移植并发症 \| 休克 \| 低血压	20	Angiotensin II	製膚齋網淵鬱膚膚範繭(築鏇簾鹽艱鬱獵獵鹹齋) = 簾糧鹹衊餘壓鏇築網顧遞襯簾壓窪觸淵鏇膚齋 (鹹鹽蓋築築網衊願築膚, 顧鑰蓋鹽築壓簾鹽積廠 ~ 獵鬱窪鹽窪築觸廠鏇夢) 更多	-	2022-12-21
ASN2022	N/A	GSTM1 deficiency	-	Angiotensin II (Gstm1 knockout (KO))	遞遞淵鑰襯製憲鑰築繭(艱蓋憲製願觸簾齋憲憲) = 簾憲鏇襯醖壓鏇膚鏇廠製鬱壓淵網膚膚憲壓蓋 (鹹觸構築獵鑰膚鹽遞窪 )	-	2022-11-05
				Angiotensin II (Wild-type (WT))	遞遞淵鑰襯製憲鑰築繭(艱蓋憲製願觸簾齋憲憲) = 獵鹽願鬱齋鬱艱積膚範製鬱壓淵網膚膚憲壓蓋 (鹹觸構築獵鑰膚鹽遞窪 )